The Radiopharmaceutical Talent Shortage: A Structural Risk for Clinical Development

Radiopharma innovation depends on a workforce the industry hasn’t built yet.

Radiopharmaceutical pipelines are expanding across new targets, radionuclides, and therapeutic indications. Yet the specialized workforce required to translate those programs into clinical studies remains comparatively limited.

This is becoming more than a hiring challenge. It is a structural development risk.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has identified workforce development as a strategic priority, including projected gaps across physicians, technologists, scientists, residents, and advanced practice providers.[1] A 2025 SNMMI workforce analysis found that approximately 20% of physicians, 30% of scientists, and 35% of technologists surveyed planned to retire within five years.[2] At the same time, radiopharmaceutical therapy volumes are expected to increase.

For development teams, the implication is clear: pipeline growth and workforce capacity are moving on different trajectories.

Radiopharma Requires a Specialized Clinical Ecosystem

Radiopharmaceutical development brings together disciplines that traditionally operate across different parts of the healthcare system.

Nuclear medicine physicians, technologists, radiochemists, radiopharmacists, medical physicists, radiation safety professionals, oncologists, nurses, and research staff may all contribute to a single program. SNMMI's criteria for comprehensive radiopharmaceutical therapy centers reflect this multidisciplinary model, requiring expertise across nuclear medicine, imaging, radiation safety, physics, and patient management.[3]

The scientific complexity continues to grow as well.

Radiopharmaceutical platforms span small molecules, peptides, and antibodies paired with radionuclides that have distinct half-lives, emissions, and biological applications.[4] Emerging alpha-emitting therapies introduce additional considerations around production, handling, dosimetry, radiation protection, and clinical implementation.

The talent requirement is therefore highly specific. Conventional oncology trial experience alone does not create radiopharmaceutical development expertise.

The Constraint Extends Across the Workforce

The most visible workforce discussion often focuses on nuclear medicine physicians, but the capacity challenge is broader.

Radiochemists and radiopharmacists support preparation, quality, and increasingly complex radionuclide platforms. Technologists manage imaging and therapy workflows. Medical physicists and radiation safety specialists help ensure appropriate dosimetry, handling, and radiation protection. Research personnel must integrate those requirements with protocol execution and sponsor expectations.

The International Atomic Energy Agency reported in 2025 that many member states face shortages of qualified nuclear medicine professionals and identified a need to update education and training for newer nuclear medicine modalities and practices.[5]

SNMMI has reached a similar conclusion. Its 2025 stakeholder work highlighted insufficient appropriately trained personnel as a barrier to expanding radiopharmaceutical therapy and emphasized the need for greater clinical expertise and broader multidisciplinary training.[6]

Theragnostic Insight: Workforce availability should be treated as a development constraint, not simply a recruitment problem. A site cannot create specialized expertise on demand when enrollment begins.

Talent Concentration Can Become Site Concentration

The workforce shortage also helps explain why radiopharmaceutical trials remain concentrated within experienced academic centers.

Those institutions have spent years building teams, radioactive-materials infrastructure, imaging capabilities, and institutional knowledge. Sponsors naturally return to sites with demonstrated experience.

But as more programs compete for the same investigators and clinical teams, experienced sites can become increasingly constrained.

Expanding into community settings offers an important pathway to additional capacity, but equipment and licenses alone are insufficient. Community expansion requires trained professionals who can execute radiopharmaceutical protocols safely and consistently.

This creates a circular challenge: the industry needs more sites to support pipeline growth, while more sites require a larger trained workforce.

Workforce Risk Belongs in Development Planning

For sponsors, workforce assessment should begin during clinical strategy and site feasibility.

Does a prospective site have qualified personnel available for the study? Are those individuals supporting competing trials or growing clinical workloads? What happens if a key technologist, physician, physicist, or radiation safety professional leaves? Can responsibilities be distributed across a trained team, or does execution depend on one or two individuals?

These questions reveal vulnerabilities that conventional feasibility assessments may miss.

The response also requires longer-term thinking. SNMMI is expanding competency-based education, therapy-intensive programs, and professional development to strengthen the workforce pipeline.[1][7] Those initiatives are important, but education and experience take time to translate into clinical capacity.

Sponsors and healthcare systems therefore have an opportunity to invest earlier in training, cross-disciplinary education, and repeatable models for developing radiopharmaceutical-capable teams.

What This Means for You

The radiopharmaceutical talent shortage has implications across the development ecosystem.

For biotech and pharma, workforce constraints can affect site activation, enrollment, protocol execution, and scalability. For healthcare systems, specialized talent may determine whether radiopharmaceutical research and therapy programs can expand sustainably. For investors, workforce readiness represents another dimension of infrastructure risk when assessing whether growing pipelines can translate into clinical progress.

Theragnostic Insights helps organizations connect these realities early—aligning development strategy with site capabilities, workforce readiness, and the practical requirements of clinical implementation.

The industry has built an increasingly sophisticated pipeline of radiopharmaceutical innovation.

Building the people capable of delivering it is now part of the development strategy.

References

[1] Society of Nuclear Medicine and Molecular Imaging, 2026. SNMMI Workforce Pipeline Domain. Workforce development initiative.  

[2] Society of Nuclear Medicine and Molecular Imaging, 2025. SNMMI/IMV Workforce Study: Critical Findings. Value Initiative.  

[3] Society of Nuclear Medicine and Molecular Imaging, 2026. Comprehensive Radiopharmaceutical Therapy Center of Excellence Requirements.  

[4] Zhang S, Wang X, Gao X, et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy, 10:1.

[5] International Atomic Energy Agency, 2025. Technical Meeting on Radiation Protection Challenges in Modern Diagnostic and Therapeutic Nuclear Medicine.  

[6] Society of Nuclear Medicine and Molecular Imaging, 2025. Theranostics Stakeholder Summit White Paper.  

[7] Society of Nuclear Medicine and Molecular Imaging, 2026. Therapy Intensives & Theranostics Certification.

‍

‍